# HRMY catalysts: Harmony Biosciences Holdings, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/hrmy/catalysts

> Harmony Biosciences Holdings, Inc. (HRMY) has 14 upcoming catalysts. The next is the Harmony Biosciences Holdings, Inc. PDUFA date, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for HRMY?

Harmony Biosciences Holdings, Inc. (HRMY) has 14 upcoming catalysts. The next is the Harmony Biosciences Holdings, Inc. PDUFA date, Q1 2027. Press release filed with the SEC (EX-99): "Anticipated PDUFA date in Q1 2027" [Calendar and source filings](https://sec-api.dev/companies/hrmy/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-056786, https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d2.htm (retrieved 2026-11-12). Last confirmed 2026-05-07. Cite: https://sec-api.dev/companies/hrmy/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Harmony Biosciences Holdings, Inc. |
| Ticker | HRMY (Nasdaq) |
| SEC CIK | 1802665 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/hrmy |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 14, 2019 | [WAKIX® (pitolisant) FDA approval](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed, approved | "NDA211150 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190814, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22)) |
| October 13, 2020 | [WAKIX® (pitolisant) FDA approval](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed, approved | "NDA211150 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20201013, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22)) |
| Apr 2022 | [WAKIX® (pitolisant) trial start](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed | "In April 2022, we initiated a Phase 3 registrational trial, the INTUNE Study, to evaluate the efficacy and safety of pitolisant in adult patients with IH." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm)) |
| Nov 2022 | [WAKIX® (pitolisant) topline data readout](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed, positive | "Topline results from this clinical proof-of-concept trial were reported in November 2022 and showed a positive signal on improvement in the primary outcome related to EDS." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm)) |
| June 21, 2024 | [WAKIX® (pitolisant) label expansion decision](https://sec-api.dev/pdufa/pitolisant) | HRMY | EDS in pediatric patients six years of age and older with narcolepsy | completed, approved | "NDA211150 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240621, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22)) |
| 2025 | [WAKIX® (pitolisant) NDA/BLA submission](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm)) |
| 2025 | [ZYN002 trial start](https://sec-api.dev/pdufa/zyn002) | HRMY | behavioral symptoms associated with 22q | scheduled | "An open-label phase 2 proof-of-concept study conducted by Zynerba showed positive signals for ZYN-002 in the treatment of behavioral symptoms associated with 22q. We plan to initiate a Phase 3 registrational study in 22q deletion syndrome in 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm)) |
| February 25, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG 2024 FINANCIAL RESULTS AND REITERATES 2025 NET REVENUE GUIDANCE; HIGHLIGHTS 2025 CATALYSTS IN SLEEP/WAKE AND FRAGILE X SYNDROME DEVELOPMENT PROGRAMS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/hrmy-20250225xex99d1.htm)) |
| May 6, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG Q1 2025 FINANCIAL RESULTS, HIGHLIGHTS ADVANCEMENT OF ITS PIPELINE AND UPCOMING CATALYSTS, AND REAFFIRMS 2025 REVENUE GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/hrmy-20250506xex99d1.htm)) |
| Q3 2025 | [WAKIX® (pitolisant) topline data readout](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "Pivotal bioequivalence study on track to initiate Q1 2025 o Topline data readout anticipated in Q3 2025 with potential PDUFA in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/hrmy-20250225xex99d1.htm)) |
| Q3 2025 | [Harmony Biosciences Holdings, Inc. topline data readout](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | scheduled | "HARMONY BIOSCIENCES REPORTS STRONG Q2 2025 FINANCIAL RESULTS AND REAFFIRMS 2025 REVENUE GUIDANCE; ON TRACK TO ANNOUNCE FRAGILE X TOPLINE DATA FROM PHASE 3 REGISTRATIONAL TRIAL IN Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm)) |
| Q3 2025 | [ZYN002 topline data readout](https://sec-api.dev/pdufa/zyn002) | HRMY |  | scheduled | "Topline Data from the Phase 3 registrational trial of ZYN002 in Fragile X syndrome on track for Q3 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm)) |
| Q3 2025 | [Harmony Biosciences Holdings, Inc. topline data readout](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | scheduled | "Topline data readout anticipated in Q3 2025 with potential PDUFA date in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/hrmy-20250506xex99d1.htm)) |
| August 5, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG Q2 2025 FINANCIAL RESULTS AND REAFFIRMS 2025 REVENUE GUIDANCE; ON TRACK TO ANNOUNCE FRAGILE X TOPLINE DATA FROM PHASE 3 REGISTRATIONAL TRIAL IN Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm)) |
| Q4 2025 | [WAKIX® (pitolisant) trial start](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "Pitolisant HD IND submitted; On Track to Initiate Phase 3 Trials in Narcolepsy and Idiopathic Hypersomnia in Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm)) |
| Q4 2025 | [WAKIX® (pitolisant) topline data readout](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "Topline data readout from pivotal BE study anticipated in Q4 2025 with potential PDUFA date in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm)) |
| October 23, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "Harmony will report full third quarter 2025 financial results on Tuesday, November 4th, 2025, before the open of the U.S. financial markets." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023xex99d1.htm)) |
| Nov 2025 | [WAKIX® (pitolisant) topline data readout](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed, positive | "We initiated the pivotal bioequivalence study in the first quarter of 2025 and announced positive topline data in November 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm)) |
| November 4, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG Q3 2025 FINANCIAL RESULTS; RECENTLY RAISED 2025 REVENUE GUIDANCE TO" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm)) |
| 2026 | [Harmony Biosciences Holdings, Inc. topline data readout](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | scheduled | "A first-in-human study is planned to begin in the second half of 2025 with topline data anticipated in 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1802665/000155837025008525/hrmy-20250611x8k.htm)) |
| 2026 | [EPX-100 topline data readout](https://sec-api.dev/pdufa/epx-100) | HRMY |  | scheduled | "o Topline data anticipated in 2026 from both the ARGUS and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d2.htm)) |
| 2026 | [Harmony Biosciences Holdings, Inc. topline data readout](https://sec-api.dev/companies/hrmy/catalysts) | HRMY | Lennox-Gastaut syndrome | scheduled | "Enrollment ongoing for Phase 3 registrational trial in Dravet syndrome (ARGUS Study) with topline data anticipated in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm)) |
| 2026 | [BP-205 NDA/BLA submission](https://sec-api.dev/pdufa/bp-205) | HRMY |  | scheduled | "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; plans to submit an NDA for Pitolisant GR; plans to submit an IND for BP-205; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm)) |
| February 13, 2026 | [WAKIX® (pitolisant) label expansion decision](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed, approved | "NDA211150 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260213, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22)) |
| February 24, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG 2025 FINANCIAL RESULTS AND REITERATES 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm)) |
| Q2 2026 | [WAKIX® (pitolisant) PDUFA date](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "Our anticipated PDUFA date for Pitolisant GR is in 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000155837025010185/hrmy-20250630x10q.htm)) |
| Q2 2026 | [WAKIX® (pitolisant) NDA/BLA submission](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "NDA submission in Q2 2026; anticipated PDUFA date in Q1 2027 o Approximately 80-90% of patients with narcolepsy experience GI symptoms; pitolisant GR is designed to minimize the worsening of these symptoms o Ability to initiate treatment at therapeutic dose with no titration" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm)) |
| May 7, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm)) |
| Jun 2026 | [WAKIX® (pitolisant) NDA/BLA acceptance](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | completed | "In June 2026, we submitted a New Drug Application ("NDA") for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act ("PDUFA") date of April 1, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm)) |
| 2H 2026 | [WAKIX® (pitolisant) topline data readout](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "o Phase 3 topline data readout expected in 2H 2026 o Supports Pediatric Exclusivity for WAKIX: Fulfills a key regulatory requirement for six months of additional regulatory exclusivity, extending exclusivity to March 2030" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm)) |
| Jul 2026 | [BP-205 trial start](https://sec-api.dev/pdufa/bp-205) | HRMY |  | completed | "In July 2026, we submitted an IND for BP-205 to the FDA, which is now open, and initiated a Phase 1b study in sleep-deprived healthy volunteers in the third quarter of 2026, with topline data expected in the first quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm)) |
| Q3 2026 | [BP-205 trial start](https://sec-api.dev/pdufa/bp-205) | HRMY |  | scheduled | "In July 2026, we submitted an IND for BP-205 to the FDA, which is now open, and are preparing to initiate a Phase 1b study in sleep-deprived healthy volunteers in the third quarter of 2026, with topline data expected in early 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm)) |
| July 16, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "Harmony will report full second quarter 2026 financial results and provide a business update on August 4, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716xex99d1.htm)) |
| Q4 2026 | [BP-205 topline data readout](https://sec-api.dev/pdufa/bp-205) | HRMY |  | scheduled | "Topline data from the Phase 1 multiple ascending dose study is expected in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm)) |
| November 4, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "Harmony Biosciences Reports Q3 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm)) |
| Q1 2027 | [Harmony Biosciences Holdings, Inc. PDUFA date](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | scheduled | "Anticipated PDUFA date in Q1 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d2.htm)) |
| early 2027 | [BP-205 trial start](https://sec-api.dev/pdufa/bp-205) | HRMY |  | scheduled | "BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm)) |
| 2027 | [Harmony Biosciences Holdings, Inc. topline data readout](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | scheduled | "Phase 3 registrational trial in narcolepsy to include endpoint on narcolepsy-related fatigue in pursuit of differentiated label o Trial to initiate in Q4 2025; topline data readout anticipated in 2027 with potential PDUFA date in 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/hrmy-20250225xex99d1.htm)) |
| Q1 2027 | [EPX-100 PDUFA date](https://sec-api.dev/pdufa/epx-100) | HRMY |  | scheduled | "ANTICIPATED PDUFA DATE Q1 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d2.htm)) |
| 1H 2027 | [EPX-100 topline data readout](https://sec-api.dev/pdufa/epx-100) | HRMY |  | scheduled | "Topline data anticipated 1H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d2.htm)) |
| Q1 2027 | [BP-205 topline data readout](https://sec-api.dev/pdufa/bp-205) | HRMY |  | scheduled | "In July 2026, we submitted an IND for BP-205 to the FDA, which is now open, and initiated a Phase 1b study in sleep-deprived healthy volunteers in the third quarter of 2026, with topline data expected in the first quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm)) |
| Q1 2027 | [WAKIX® (pitolisant) PDUFA date](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "NDA submission in Q2 2026; anticipated PDUFA date in Q1 2027 o Approximately 80-90% of patients with narcolepsy experience GI symptoms; pitolisant GR is designed to minimize the worsening of these symptoms o Ability to initiate treatment at therapeutic dose with no titration" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm)) |
| April 1, 2027 | [WAKIX® (pitolisant) NDA/BLA acceptance](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "NDA accepted by FDA in July; target PDUFA date of April 1, 2027 o Designed with enteric coating meant to reduce the potential for GI side effects in patients with narcolepsy, 80 - 90% of whom experience GI symptoms as part of their disease o Enables patients to initiate treatment at a therapeutic dose without titration, an important clinical differentiation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm)) |
| April 1, 2027 | [WAKIX® (pitolisant) PDUFA date](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "Pitolisant GR NDA Under FDA Review, PDUFA Date April 1, 2027; Pitolisant HD Phase 3 Topline Data in 2027, Target PDUFA Date in 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm)) |
| mid-2027 | [WAKIX® (pitolisant) topline data readout](https://sec-api.dev/pdufa/pitolisant) | HRMY | Lennox- Gastaut syndrome | scheduled | "Topline data expected in mid-2027 and anticipated PDUFA date in 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm)) |
| 2028 | [WAKIX® (pitolisant) PDUFA date](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "Pitolisant HD On Track for Phase 3 Topline Data in 2027 and Target PDUFA Date in 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm)) |
| 2028 | [BP-205 PDUFA date](https://sec-api.dev/pdufa/bp-205) | HRMY |  | scheduled | "TLD expected in 2027; Anticipated PDUFA in 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d2.htm)) |
| 2028 | [EPX-100 PDUFA date](https://sec-api.dev/pdufa/epx-100) | HRMY |  | scheduled | "Topline data readouts anticipated in 2027; PDUFA dates anticipated in 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d2.htm)) |
| 2028 | [Harmony Biosciences Holdings, Inc. PDUFA date](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | scheduled | "o Topline data expected in 2027 and anticipated PDUFA date in 2028 o Enhanced formulation with optimized PK profile, enteric coating and higher dose to drive greater efficacy o Pursuing differentiated labeling: fatigue in narcolepsy and sleep inertia in IH" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm)) |

## Drugs

- [BP-205](https://sec-api.dev/pdufa/bp-205): 
- [EPX-100](https://sec-api.dev/pdufa/epx-100): 
- [WAKIX® (pitolisant)](https://sec-api.dev/pdufa/pitolisant): eds in pediatric patients six years of age and older with narcolepsy, lennox-gastaut syndrome, lennox- gastaut syndrome
- [ZYN002](https://sec-api.dev/pdufa/zyn002): behavioral symptoms associated with 22q

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/hrmy/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HRMY catalysts: Harmony Biosciences Holdings, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/hrmy/catalysts

```bibtex
@misc{secapidev_companies_hrmy_catalysts_20261116,
  title        = {HRMY catalysts: Harmony Biosciences Holdings, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/hrmy/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_hrmy_catalysts_20261116","title":"HRMY catalysts: Harmony Biosciences Holdings, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/hrmy/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
